Picture of Taisho Pharmaceutical Holdings Co logo

4581 — Taisho Pharmaceutical Holdings Co News Story

0.000.00%
jp flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Takeda feeling uncomfortable Shire side effects

(The author is a Reuters Breakingviews columnist.  The opinions
expressed are her own.)
    By Sharon Lam
    HONG KONG, July 13 (Reuters Breakingviews) - The Japanese
drugmaker is near a deal that would get it to a $10 bln
divestiture target 18 months after buying its Irish rival for
$62 bln. Promised cost savings are materialising and debt slowly
shrinking. Weak stock performance under boss Christophe Weber
suggests he overpaid.
    Full view will be published shortly.
    On Twitter https://twitter.com/sharonlamhk
    

    CONTEXT NEWS
    - - Taisho Pharmaceutical and buyout firms Blackstone and
Bain Capital are among the final bidders for Takeda
Pharmaceutical’s consumer business in Japan, a deal that could
be worth up to 400 billion yen ($3.7 billion), Reuters reported
on June 19, citing unnamed sources. Takeda has not confirmed the
media reports.
    - For previous columns by the author, Reuters customers can
click on  LAM/ 
    - SIGN UP FOR BREAKINGVIEWS EMAIL ALERTS: http://bit.ly/BVsubscribe

    <^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Reuters: Blackstone, Taisho Pharma among final bidders for
Takeda's Japan OTC unit – sources     urn:newsml:reuters.com:*:nL4N2DW1JR
    ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>
 (Editing by Jeffrey Goldfarb and Jamie Lo)
 ((sharon.lam@thomsonreuters.com; Reuters Messaging:
sharon.lam.thomsonreuters.com@reuters.net))

Recent news on Taisho Pharmaceutical Holdings Co

See all news